| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:47 UTC |
|---|
| HMDB ID | HMDB0014934 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Candesartan |
|---|
| Description | Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. |
|---|
| Structure | CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1 InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Ethoxy-1-(p-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid | ChEBI | | 2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid | ChEBI | | 2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4Ethyl]}-1H-benzimidazole-7-carboxylic acid | ChEBI | | Blopress | ChEBI | | CV-11974 | ChEBI | | 2-Ethoxy-1-(p-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate | Generator | | 2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate | Generator | | 2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4Ethyl]}-1H-benzimidazole-7-carboxylate | Generator | | Candesartan cilexetil | HMDB | | 2-Ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole | HMDB |
|
|---|
| Chemical Formula | C24H20N6O3 |
|---|
| Average Molecular Weight | 440.454 |
|---|
| Monoisotopic Molecular Weight | 440.159688536 |
|---|
| IUPAC Name | 2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid |
|---|
| Traditional Name | candesartan |
|---|
| CAS Registry Number | 139481-59-7 |
|---|
| SMILES | CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1 |
|---|
| InChI Identifier | InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) |
|---|
| InChI Key | HTQMVQVXFRQIKW-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Biphenyls and derivatives |
|---|
| Direct Parent | Biphenyls and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Biphenyl
- Phenyltetrazole
- Benzimidazole
- Alkyl aryl ether
- N-substituted imidazole
- Azole
- Imidazole
- Heteroaromatic compound
- Vinylogous amide
- Tetrazole
- Carboxylic acid derivative
- Carboxylic acid
- Ether
- Monocarboxylic acid or derivatives
- Azacycle
- Organoheterocyclic compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxide
- Organonitrogen compound
- Organooxygen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0077 g/L | Not Available | | LogP | 6.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.47 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.4841 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.92 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 45.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3009.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 309.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 202.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 196.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 274.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 555.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 601.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 78.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1265.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 588.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1477.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 405.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 376.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 228.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 121.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Candesartan,1TMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1 | 3915.3 | Semi standard non polar | 33892256 | | Candesartan,1TMS,isomer #2 | CCOC1=NC2=CC=CC(C(=O)O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 4174.2 | Semi standard non polar | 33892256 | | Candesartan,2TMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 4070.0 | Semi standard non polar | 33892256 | | Candesartan,2TMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 3948.4 | Standard non polar | 33892256 | | Candesartan,2TMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1 | 5229.6 | Standard polar | 33892256 | | Candesartan,1TBDMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C(C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1 | 4114.7 | Semi standard non polar | 33892256 | | Candesartan,1TBDMS,isomer #2 | CCOC1=NC2=CC=CC(C(=O)O)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4298.7 | Semi standard non polar | 33892256 | | Candesartan,2TBDMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C(C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4367.9 | Semi standard non polar | 33892256 | | Candesartan,2TBDMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C(C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 4311.2 | Standard non polar | 33892256 | | Candesartan,2TBDMS,isomer #1 | CCOC1=NC2=CC=CC(C(=O)O[Si](C)(C)C(C)(C)C)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1 | 5185.7 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Candesartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-001r-1379500000-3bae4ca1aa6a86854b96 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Candesartan GC-MS (1 TMS) - 70eV, Positive | splash10-000i-2090600000-cf7635060443e14480cc | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Candesartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-QTOF , negative-QTOF | splash10-000i-0000900000-09252e3705ec18f28191 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-QTOF , negative-QTOF | splash10-0a4r-0319500000-3993447974e9c0f96e19 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-QTOF , negative-QTOF | splash10-0bu0-0916000000-066da93a95b0b10a64f7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-QTOF , negative-QTOF | splash10-001i-0901000000-e42def94ea7acc3e984c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-QTOF , negative-QTOF | splash10-001i-0902000000-9d8d5d747fc07188bcd6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0009000000-3f09ac2e45a45cf51567 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-000i-0000900000-c0732b3f672bdb0c5cd9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0429000000-e6666ddaea6b2fec4796 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-053r-0925000000-b2853a4d3ef881471918 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0901000000-e8293134d3b6edc1cc44 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0900000000-aad7b334b76f7066ae1e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0900000000-e9298a423fa741683f4d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-000i-0000900000-4332e0602a564f2c4578 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0329000000-5bab9c66bf500046dd03 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-053r-0934000000-07766836cd4310e3c144 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0911000000-b335b08ddf551145ef5c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0900000000-7cd909aa2c285aa2e22b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0900000000-bf38bb169df6697bd345 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candesartan LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0009000000-dffef5ed5958e9c3aa46 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 10V, Positive-QTOF | splash10-0006-0033900000-ef0f58fc5acd71bde733 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 20V, Positive-QTOF | splash10-01p2-0149500000-79b1615f1bd726ee7e68 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 40V, Positive-QTOF | splash10-000i-1494000000-a1d1f564d6511df7d18e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 10V, Negative-QTOF | splash10-000b-1129700000-4fa25e76b08cfd8f17f7 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 20V, Negative-QTOF | splash10-0002-0419100000-c08be01eacdc406a9ec8 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candesartan 40V, Negative-QTOF | splash10-0bvj-4901000000-e2848511241bc912e43c | 2016-08-04 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275 ]
- Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650 ]
- Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. [PubMed:13678868 ]
- (). Bader, M. (2004). Renin-angiotensin-aldosterone system. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology_ (pp. 810-814). Berlin, Germany: Springer. . .
- (). Stanfield, C.L., & Germann, W.J. (2008). Principles of human physiology (3rd ed.). San Francisco, CA: Pearson Education, Inc.. .
|
|---|